Book A call



Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.

Going beyond breakthroughs

We understand that psychedelics are powerful medicines, but not magic pills. We understand that they can profoundly change lives, families, and communities, and that success requires more than just a breakthrough experience—it also takes careful, sensitive attention to every individual’s story, mindful preparation, and a grounded, realistic plan for what comes after.

Multidisciplinary expertise with human-centred care

Numinus boasts a diverse and interdisciplinary team of professionals, from physicians and psychiatrists to mindfulness teachers, nurses and psychotherapists, researchers and technicians. Our protocols are backed by rigorous science, and delivered by a team that understands that even the best tools still require genuine human care to be effective.

Curiosity and humility

At the core of what we do at Numinus is a deep sense of curiosity and humility about everything we encounter. We know that psychedelics, mindfulness, and embodied practices are not new tools, but rather owe a debt to some very old ways of being and caring for one another. We’re working every day to honour that wisdom and those traditions, and integrating it with the best that modern science has to offer.


View All Members


Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness
Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms. Click here to read more.
February 19, 2021
Numinus Wellness's trial for MDMA-assisted therapy is in pre-implementation stage
The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has successfully transitioned into the 'pre-implementation stage' at […]
February 18, 2021
FR: Numinus annonce des avancées dans les essais cliniques à accès compassionnel pour la thérapie assistée par MDMA en collaboration avec MAPS Public Benefit Corporation
Les essais cliniques entrent en phase préparatoire après avoir franchi plusieurs jalons importants en vue d’étendre l’accès aux patients souffrant de SSPT (Syndrome de stress post-traumatique) VANCOUVER (Le 18 février […]
February 18, 2021
1 12 13 14 15 16 36
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram